Novo Nordisk A/S has announced the official launch of a higher-dose version of its weight-loss medication, Wegovy, in the United States. The 7.2-milligram dose, branded as Wegovy HD, was made available on Tuesday following its approval by the FDA last month under the National Priority Review Voucher program. This release marks a significant increase from the previous maximum authorized dosage of 2.4 mg for the injectable treatment.
Novo Nordisk Launches Higher-Dose Wegovy HD Weight Loss Drug
Novo Nordisk launched its 7.2-milligram Wegovy HD weight-loss drug in the United States today. Cash-paying patients can expect to pay $399 per month for it.
Xurve View
洞察:
Xurve View
The company confirmed that Wegovy HD is accessible through retail pharmacies, NovoCare Pharmacy, and selected telehealth platforms. For adults paying without insurance, the monthly cost is approximately $399. Patients with commercial insurance coverage may be eligible for a savings program that brings the price down to $25 per month.










